Lancashire and South Cumbria
Formulary
Formulary
21 Palliative Care Formulary
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
21 Palliative Care Formulary Drugs
| Cyclizine |
|
Formulary
|
Palliative care Nausea and vomiting Nausea and vomiting in the last days of life Opioid-induced nausea and vomiting |
|
| Fentanyl |
|
Formulary
|
Palliative care Pain |
 MHRA: Fentanyl skin patches: How to use and dispose of them safely MHRA: Serious and fatal overdose of fentanyl patches |
|
|
| Hyoscine hydrobromide |
|
Formulary
|
Palliative care Respiratory tract secretions in the last days of life |
|
|
| Morphine |
|
Formulary
|
Palliative care Breathlessness Pain in the last weeks or days of life Breathlessness in the last days of life Pain |
|
|
| Octreotide |
|
Formulary
|
Palliative care Bowel obstruction - GI secretions associated with bowel obstruction. |
|
|
| Ondansetron |
|
Formulary
|
Palliative care Bowel obstruction - nausea and vomiting associated with bowel obstruction |
|
|
| Oxycodone |
|
Formulary
|
Palliative care Breathlessness in the last days of life (on the advice of a specialist) |
|
|
Links
- Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**
- Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
- LSCMMG: Atrial Fibrillation
- LSCMMG: Heart Failure - Primary Care Guideline for the Use of SGLT-2 Inhibitors in Reduced Ejection Fraction Heart Failure
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- LSCMMG: Low Molecular Weight Heparins (LMWHs) Summary Prescribing Guide
- MHRA Drug Safety Update : Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations
- MHRA Drug Safety Update Jan 2019: Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines
- MHRA: Clopidogrel and proton pump inhibitors: interaction—updated advice
- MHRA: Fentanyl skin patches: How to use and dispose of them safely
- MHRA: Serious and fatal overdose of fentanyl patches
- NG 185 - Acute coronary syndromes
- NG 196 - Atrial fibrillation: diagnosis and management
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- Palliative care: Bowel obstruction
- Palliative care: Breathlessness
- Palliative care: Care in the last weeks or days of life
- Palliative care: Complex pain
- Palliative care: Constipation
- Palliative care: Corticosteroids
- Palliative care: Emergencies
- Palliative care: Nausea & vomiting
- Palliative care: Pain